Zenas BioPharma, Inc. (ZBIO)
27.48
-2.16
(-7.27%)
USD |
NASDAQ |
Sep 24, 16:00
27.48
0.00 (0.00%)
After-Hours: 19:59
Zenas BioPharma Total Assets (Quarterly) : 701.69M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 701.69M |
| March 31, 2026 | 747.68M |
| December 31, 2025 | 383.64M |
| September 30, 2025 | 322.02M |
| June 30, 2025 | 293.08M |
| March 31, 2025 | 333.77M |
| Date | Value |
|---|---|
| December 31, 2024 | 369.97M |
| September 30, 2024 | 403.43M |
| June 30, 2024 | 199.95M |
| March 31, 2024 | 49.05M |
| December 31, 2023 | 68.18M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.743B |
| Alnylam Pharmaceuticals, Inc. | 5.559B |
| Anika Therapeutics, Inc. | 183.47M |
| Savara, Inc. | 192.14M |
| Vericel Corp. | 502.87M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 454.59M |
| Shareholders Equity (Quarterly) | 247.10M |
| Debt to Equity Ratio | 1.577 |
| Current Ratio | 9.933 |
| Net Debt Paydown Yield | -4.83% |